CTCX Carmell Therapeutics: Price-to-Projected Revenue Ratio

Carmell Corporation - graphic logo of issuer CTCX

Carmell Corporation is developing advanced nano-polymers for tissue regeneration. The forward price-to-sales valuation demonstrates price action where the value 1.60 describes the current level. Growth is driven by demand from aesthetic medicine clinics for plasma platforms. The primary catalysts are the commercialization of wound-healing products and expansion into the orthopedic sector.

Carmell - CTCX Market Cap to Expected Sales Ratio (period 04/05/2024 - 12/31/2024)

Summary analytical data breakdowns for Carmell Corporation (CTCX)

- market price and analyst price targets:
Analysis of all company metrics:Carmell Corp. CTCX
Original product of Carmell Therapeutics

Carmell Corporation (CTCX) is optimizing costs by utilizing a flexible network of contract laboratories for the production of biomaterials and packaging. The forward P/S ratio measures market value relative to expected revenue, reflecting the business's ability to pass inflation onto consumers, which, combined with the expected P/S dynamics on GURU.Markets, allows investors to distinguish between searching for a market bottom and a dangerous value trap.

Competitors of Carmell Corporation

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio newamsterdampharma.com (NAMS)|Forward Price-to-Revenue Multiple soleno.life SLNO|Forward P/S Multiple FOLD (amicusrx.com)|Market Cap to Expected Sales Ratio 89bio (ETNB)|Agios - Forward P/S Multiple|Structure Corp - Price to Expected Revenue Ratio|mimedx.com (MDXG) - Price-to-Projected Revenue Ratio|Future Price to Revenue RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MBX|Price-to-Projected Revenue Ratio Altimmune Pharma (ALT)|Price-to-Projected Revenue Ratio AARD (Aardvark Therapeutics Corp)|Forward P/S Multiple SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Market Cap to Future Revenue Ratio|BMEA: Forward Price-to-Revenue Multiple|Forward Price to Sales QNCX (Quince Therapeutics Inc)|GUTS (Fractyl) - Forward Price-to-Revenue Multiple|vTv Therapeutics, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Agape ATP Corp.|Forward Price-to-Revenue Multiple Pluri (PLUR)|Forward P/S Multiple SYBX|Market Cap to Expected Sales Ratio Lipocine Inc|Price-to-Projected Revenue Ratio Matinas BioPharma Holdings MTNB|Market Cap to Expected Sales Ratio Spruce Biosciences (SPRB)|GLTO: Forward Price-to-Revenue Multiple|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio